http://jcps.bjmu.edu.cn

• 研究论文 • 上一篇    下一篇

环维黄杨星D抑制凝血和静脉血栓形成

刘秀梅, 刘晓岩, 王银叶*, 陈世忠   

  1. 1. 北京大学医学部 药学院 分子与细胞药理学系, 北京 100191
    2. 北京大学医学部 药学院 天然药物学系, 北京 100191
  • 收稿日期:2009-12-04 修回日期:2010-02-10 出版日期:2010-03-15 发布日期:2010-03-15
  • 通讯作者: 王银叶*

Cyclovirobuxine D inhibits blood coagulation and venous thrombosis

Xiu-Mei Liu, Xiao-Yan Liu, Yin-Ye Wang*, Shi-Zhong Chen   

  1. 1. Department of Molecular and Cellular Pharmacology, School of Pharmceutical Sciences, Peking University Health Science Center, Beijing 100191, China
    2. Department of Natural Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • Received:2009-12-04 Revised:2010-02-10 Online:2010-03-15 Published:2010-03-15
  • Contact: Yin-Ye Wang*

摘要: 环维黄杨星D (Cyclovirobuxine D) 系从黄杨科植物小叶黄杨 (Buxus microphylla Sieb. et Zucc. var. Sinica Rehd. et Wils.) 及其同属植物中提取的一种生物碱, 在我国主要用于治疗心律失常和心肌缺血。在此项研究中, 我们观测环维黄杨星D的抗凝血作用及对静脉血栓形成的影响。研究结果表明, 与对照组相比, 环维黄杨星D低、中、高剂量 (5~20 mg/kg) 能剂量依赖地延长小鼠的凝血时间 (P<0.01); 中、高剂量 (10~20 mg/kg) 能延长PT、aPTT和TT (P<0.05或P<0.01); 环维黄杨星D低、中、高剂量 (5~20 mg/kg) 均未明显延长小鼠的出血时间; 环维黄杨星D低、中、高剂量 (5~20 mg/kg) 均能抑制小鼠和大鼠静脉血栓的形成。本文首次证明环维黄杨星D口服具有显著的抗凝血以及抑制静脉血栓形成的作用, 其出血副作用轻微, 提示它可能作为口服抗凝血药。

关键词: 环维黄杨星D, 凝血, 静脉血栓, 出血时间

Abstract: Cyclovirobuxine D (CVB-D) is a compound extracted from Chinese traditional plant Buxus microphylla, which has been used for treating arrhythmia and myocardial ischemia in China. In this study, we investigated its effect on blood coagulation and thrombotic formation in mouse and rat models. The doses of CVB-D used in this study (5-20 mg/kg) prolonged clotting time (CT) in a dose-dependent manner (P<0.01). It also significantly prolonged thrombin time (TT), prothrombin time (PT) and activated partial thromboplast time (aPTT) (P<0.05 or P<0.01) at the doses of 10-20 mg/kg. CVB-D did not affect the bleeding time (BT) compared with the control group, while warfarin significantly prolonged the bleeding time. CVB-D at the doses of 5-20 mg/kg reduced wet weight of thrombosis (P<0.01). This study demonstrated the anti-coagulation effect and anti-thrombosis effect of orally administered CVB-D without substantially increasing bleeding. These findings suggest that CVB-D probably can be used as an oral anti-coagulant in addition to its current applications.

Key words: Cyclovirobuxine D, Coagulation, Venous thrombosis, Bleeding time

中图分类号: 

Supporting: *Corresponding author. Tel.: 86-10-82802652